Comparison of Plasma p-tau217 and [ <sup>18</sup> F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia
Kely Quispialaya, Joseph Therriault, Antonio Aliaga, Andréa Lessa Benedet, Nicholas J. Ashton, Thomas K. Karikari, Arthur C. Macedo, Nesrine Rahmouni, Cécile Tissot, Jaime Fernández Arias, Yi-Ting Tina Wang, Lydia Trudel, Seyyed Ali Hosseini, Takashi Matsudaira, Tevy Chan, Tharick A. Pascoal, Brian M. Gilfix, Paolo Vitali, Eduardo R. Zimmer, Karine Provost, Jean‐Paul Soucy, Serge Gauthier, Henrik Zetterberg, Bertrand J. Jean‐Claude, Kaj Blennow, Pedro Rosa‐Neto
Abstract
BACKGROUND AND OBJECTIVES: F]FDG-PET in individuals who meet appropriate use criteria for Alzheimer dementia (AD) biomarker assessments. METHODS: F]FDG-PET scan interpretation and plasma p-tau217 for an AD biomarker profile in CSF and for amyloid-PET positivity. RESULTS: = 0.02). The same pattern of results was observed when using amyloid-PET as the reference standard. DISCUSSION: Our study provides evidence that plasma p-tau217 has strong discriminative accuracy for AD among patients with early-onset and/or atypical dementia assessed in specialized settings. Future work should replicate these findings in secondary care settings.